Introduction: Severe depression is prevalent in young persons and can lead to disability and elevated suicidal risk. Objectives: To identify clinical and demographic factors associated with the severity of depression in juveniles diagnosed with a major mood disorder, as a contribution to improving clinical treatment and reducing risk of suicide. Methods: We analyzed factors associated with depression severity in 270 juveniles (aged 6–18 years) in a major depressive episode, evaluated and treated at the Bambino Gesù Children’s Hospital of Rome. Depressive symptoms were rated with the revised Children’s Depression Rating Scale (CDRS-R) and manic symptoms with the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) Mania Rating Scale (K-SADS-MRS). Bivariate comparisons were followed by multivariable linear regression modeling. Results: Depression severity was greater among females than males (55.0 vs. 47.2), with the diagnosis of a major depressive disorder (MDD) vs. bipolar disorder (BD; 53.8 vs. 49.3), and tended to increase with age (slope = 1.14). Some symptoms typical of mania were associated with greater depression severity, including mood lability, hallucinations, delusions, and irritability, whereas less likely symptoms were hyperactivity, pressured speech, grandiosity, high energy, and distractibility. Factors independently and significantly associated with greater depression severity in multivariable linear regression modeling were: MDD vs. BD diagnosis, female sex, higher anxiety ratings, mood lability, and irritability. Conclusions: Severe depression was significantly associated with female sex, the presence of some manic or psychotic symptoms, and with apparent unipolar MDD. Manic/psychotic symptoms should be assessed carefully when evaluating a juvenile depressive episode and considered in treatment planning in an effort to balance risks of antidepressants and the potential value of mood-stabilizing and antimanic agents to decrease the severity of acute episodes and reduce suicidal risk.
Background:
Gender differences have been reported in the severity and psychopathological
features of major depressive disorders among adults but are poorly reported in adolescent samples.
Objective:
This study aimed to examine gender differences in the psychopathology of mixed
depression among adolescents.
Methods:
We analyzed 341 outpatients with the current major depressive episode (MDE)
retrospectively to identify patients with DSM-5 MDE with mixed features. We compared examiner-
rated depressive and (hypo)manic symptoms and self- and parent-reported symptoms between
sexes.
Results:
We identified 76 patients with an MDE with mixed features (67.1% females, 32.9% with
bipolar disorder).
Depression severity was significantly greater in females versus males (CDRS-R total score 56.2 vs.
48.2, p=0.014). Depressive symptoms were significantly and independently found to be more
severe among females in a logistic regression model, including excessive fatigue (OR 1.68;
p=0.025), low self-esteem (OR 1.67; p=0.04), excessive weeping (OR 1.62; p=0.021), and CBCL
AAA index (OR 1.04; p=0.015). None of the depressive symptoms scored greater in males. Males
had higher levels of motor activity (2.12 vs. 1.69; p=0.048) and pressured speech (1.80 vs. 1.24;
p=0.004). Self-rated anxiety (69.3 vs 56.8, p=0.047) and CBCL AAA index (207 vs 189; p=0.007)
were higher in females.
Conclusion:
Adolescent depression with mixed features is more severe in women, with a higher
expression of core affective symptoms and excessive fatigue. While in males, slightly higher levels
of psychomotor activation are reported, in females, emotional dysregulation and excessive weeping
may subtend a difference in a broader spectrum of mixed features.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.